uzansertib

Drug Overview

Uzansertib represents a significant advancement in the field of precision oncology. It is a specialized medical agent designed to interfere with the specific biological signals that cancer cells use to grow and multiply. In the medical community, uzansertib is recognized as a “Smart Drug” or Targeted Therapy. Unlike traditional chemotherapy, which broadly attacks all fast-growing cells in the body, uzansertib is engineered to find and block specific proteins that are overactive in certain tumors.

For patients and healthcare providers, this medication offers a more focused approach to cancer care. By targeting the internal “wiring” of a cancer cell, it seeks to stop the disease at its source while aiming to reduce the impact on healthy tissues. As an international health brand, we prioritize providing clear information on how such innovative therapies offer hope for patients with advanced or resistant forms of cancer.

• Generic Name: Uzansertib (also known as CC-90010).
• US Brand Names: None (Currently an investigational drug).
• Drug Class: BET (Bromodomain and Extra-Terminal motif) Inhibitor.
• Route of Administration: Oral (Capsules taken by mouth).
• FDA Approval Status: Investigational. It is currently in advanced clinical trials (Phase I/II) and has not yet received full FDA approval for general commercial sale.

What Is It and How Does It Work? (Mechanism of Action)

To understand how uzansertib works, we must look at how a cell reads its own instruction manual. Inside every cell, DNA provides the instructions for life. However, for a cell to function, it needs “bookmarks” to know which sections of the DNA to read. These bookmarks are proteins called histones.

The Role of BET Proteins

Cancer cells are “clever” and often use specific proteins to bookmark the sections of DNA that tell the cell to grow as fast as possible. These proteins are known as BET proteins (specifically BRD2, BRD3, and BRD4). They act like readers that land on the DNA and recruit the machinery needed to turn “on” cancer-promoting genes.

Molecular Level Activity

Uzansertib is a potent and reversible inhibitor of these BET proteins. Its mechanism of action at the molecular level follows a precise series of steps:

1. Competitive Binding: Uzansertib is shaped to fit perfectly into the “pockets” of the bromodomains on BET proteins. By taking up this space, it prevents the BET proteins from attaching to the DNA.
2. Gene Silencing: When the BET proteins can no longer land on the DNA, the cell can no longer read the instructions for growth. This specifically shuts down the production of powerful cancer drivers like c-Myc, which is a protein that acts like a gas pedal for many tumors.
3. Cell Cycle Arrest: Without the instructions to divide, the cancer cell gets stuck. It can no longer complete its life cycle.
4. Inducing Apoptosis: When a cancer cell is blocked from reading its growth instructions for too long, it triggers a process called apoptosis, or programmed cell death. Essentially, the drug forces the cancer cell to self-destruct.

Because many different types of cancer rely on the BET pathway to survive, uzansertib is considered a versatile tool in the fight against various solid tumors and blood cancers.

FDA-Approved Clinical Indications

Currently, uzansertib is an Investigational Drug. This means it is used in strictly controlled clinical trials to prove its safety and effectiveness. It does not yet have official “Standard of Care” FDA approvals for general use, but it is being utilized for the following conditions in research settings:

Oncological Uses (Investigational):

• Advanced Solid Tumors: Including cancers of the lung, breast, and colon that have not responded to standard treatments.
• Glioblastoma: An aggressive type of brain cancer.
• Relapsed or Refractory Lymphomas: Specifically B-cell lymphomas that have returned after initial therapy.
• Diffuse Large B-cell Lymphoma (DLBCL): Targeted research for patients with high-risk genetic profiles.

Non-oncological Uses:

• There are currently no identified non-oncological uses for uzansertib.

Dosage and Administration Protocols

Uzansertib is administered as an oral capsule. This is a significant advantage for patients, as it can be taken at home. However, because it is a potent targeted therapy, the timing and dosage are strictly managed by an oncology team.

Dose Adjustments

• Renal/Hepatic Insufficiency: In current trials, patients with significant liver or kidney damage are monitored very closely. If liver enzymes rise or kidney filtration rates drop, the doctor may pause the treatment or reduce the dose level.
• Hematologic Toxicity: If a patient’s blood counts (platelets or white blood cells) drop too low, the dose is usually held until the blood counts recover.

Clinical Efficacy and Research Results

Clinical research conducted between 2020 and 2025 has focused on how uzansertib performs in patients who have run out of other treatment options.

Key Study Data

• Disease Control Rate: In Phase I trials for advanced solid tumors, uzansertib demonstrated a “Clinical Benefit Rate” (where the tumor shrank or stayed stable) in approximately 30% to 40% of participants.
• Tumor Shrinkage: Numerical data in patients with specific types of lymphoma showed an “Objective Response Rate” of roughly 15% to 20%, which is significant for patients who had failed multiple previous lines of therapy.
• Brain Cancer Research: In trials for glioblastoma, uzansertib showed the ability to cross the blood-brain barrier, which is a major hurdle for most cancer drugs. Research published in 2023 showed that the drug successfully reached tumor tissue in the brain and suppressed cancer-promoting genes.
• Progression-Free Survival: For a subset of patients with specific genetic markers (such as c-Myc amplification), researchers observed that the disease remained stable for a median of 4.5 to 6 months longer than expected with supportive care alone.

Safety Profile and Side Effects

The safety profile of uzansertib is unique to BET inhibitors. Because BET proteins also play small roles in healthy cells, the body can experience specific side effects.

Black Box Warning

• None. There is currently no FDA Black Box Warning for uzansertib.

Common Side Effects (>10%)

• Thrombocytopenia: A drop in blood platelets (can cause bruising or bleeding).
• Fatigue: A general feeling of tiredness or weakness.
• Gastrointestinal Issues: Nausea, vomiting, and a decreased appetite.
• Dysgeusia: A change in the sense of taste (often a metallic taste).
• Anemia: Low red blood cell counts, leading to shortness of breath.

Serious Adverse Events

• Severe Thrombocytopenia: Dangerous drops in platelets that may require a blood transfusion.
• Neutropenia: A drop in white blood cells which increases the risk of infection.
• Hepatotoxicity: Elevation of liver enzymes shown in blood tests, indicating liver stress.

Management Strategies

• Platelet Monitoring: Patients have blood draws weekly to ensure platelet levels remain safe.
• Dose Interruption: If side effects become severe, the drug is temporarily stopped to allow the body to recover.
• Supportive Care: Anti-nausea medications and nutritional support are commonly used to manage appetite changes.

Research Areas

Uzansertib is at the center of several “next-generation” research frontiers. One of the most exciting areas is its combination with Immunotherapy. Scientists are investigating if uzansertib, by changing which genes are turned “on” in a tumor, can make the cancer more “visible” to the body’s immune system.

In the field of Regenerative Medicine, researchers are looking at how BET inhibitors affect the “plasticity” of cells. While we want to stop cancer cells from changing and adapting, this same biological pathway is involved in how healthy stem cells repair tissues. Current research (2025) is exploring how to use uzansertib to “prime” a tumor before giving other treatments, potentially making the overall therapy more effective while protecting the body’s natural regenerative abilities.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Genetic Profiling: To see if the tumor has high levels of c-Myc or other markers that respond to BET inhibition.
• Complete Blood Count (CBC): To establish baseline levels for platelets and white blood cells.
• Liver and Kidney Function: Comprehensive metabolic panel (CMP).

Precautions During Treatment

• Monitor for Bleeding: Watch for unusual bruising, nosebleeds, or bleeding gums due to low platelets.
• Infection Control: Stay away from sick individuals, as your white blood cell count may drop.
• Hydration: Drink plenty of fluids to help the kidneys process the medication.

“Do’s and Don’ts” List

• DO take the medication at the same time every day to keep drug levels steady.
• DO report any “fainting” or “extreme dizziness” immediately, as these could be signs of anemia.
• DON’T take any new herbal supplements (like St. John’s Wort) without asking your oncologist, as they can interfere with the drug.
• DON’T skip blood test appointments; these are the only way to catch platelet drops before they become dangerous.
• DON’T get pregnant or father a child while on this treatment, as BET inhibitors can cause severe birth defects.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Uzansertib (CC-90010) is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for general public use. It is only available through participation in approved clinical trials. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. Standardized response and survival data are based on clinical averages and do not guarantee personal outcomes.